Cargando…
Endostatin a Potential Biomarker for Heart Failure with Preserved Ejection Fraction
BACKGROUND: Endostatin is a circulating endogenous angiogenesis inhibitor preventing neovascularization. Previous studies demonstrated the prognostic value of Endostatin among patients with heart failure with reduced ejection fraction (HFrEF). However, the role of Endostatin among patients with hear...
Autores principales: | Barroso, Michael Coll, Boehme, Philip, Kramer, Frank, Mondritzki, Thomas, Koehler, Till, Gülker, Jan-Erik, Karoff, Martin, Dinh, Wilfried |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedade Brasileira de Cardiologia - SBC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729781/ https://www.ncbi.nlm.nih.gov/pubmed/28977054 http://dx.doi.org/10.5935/abc.20170144 |
Ejemplares similares
-
Serum insulin-like growth factor-1 and its binding protein-7: potential novel biomarkers for heart failure with preserved ejection fraction
por: Barroso, Michael Coll, et al.
Publicado: (2016) -
Biomarkers in heart failure with preserved ejection fraction
por: Meijers, W. C., et al.
Publicado: (2016) -
Biomarkers in Heart Failure with Preserved Ejection Fraction
por: Bayes-Genis, Antoni, et al.
Publicado: (2022) -
Test-Retest Reliability of Non-Invasive Cardiac Output Measurement
during Exercise in Healthy Volunteers in Daily Clinical Routine
por: Barroso, Michael Thomas Coll, et al.
Publicado: (2019) -
Reduced global longitudinal strain in association to increased left ventricular mass in patients with aortic valve stenosis and normal ejection fraction: a hybrid study combining echocardiography and magnetic resonance imaging
por: Dinh, Wilfried, et al.
Publicado: (2010)